NEWSTIER

H2O America Receives Regulatory Approval for Texas Subsidiary’s Acquisition of Quadvest | SAN JOSE, Calif. and MAGNOLIA, Texas, Aug. 17, 2026 (GLOBE NEWSWIRE) -- H2O America (NASDAQ: HTO) today announced that its regulated Texas water and wastewater utility, The Texas Water Company, Inc. (“TWC”), a…

Press Release: H2O America Receives Regulatory Approval for Texas Subsidiary's Acquisition of Quadvest | SAN JOSE, Calif. and MAGNOLIA, Texas, Aug. 17, 2026 (GLOBE NEWSWIRE) -- H2O America (NASDAQ: HTO) today announced that its regulated Texas water and wastewater utility, The Texas Water Company,…

*H2O America Receives Regulatory Approval For Texas Subsidiary's Acquisition Of Quadvest >HTO | (MORE TO FOLLOW) Dow Jones Newswires 08-17-26 1836ET Copyright (c) 2026 Dow Jones & Company, Inc.

Blue Jay Gold Announces Approval for Listing on the OTCQB® Venture Market in the United States | VANCOUVER, British Columbia, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Blue Jay Gold Corp. (TSXV: JAY) (FSE: JAY) (“Blue Jay” or the “Company”), is pleased to announce that it has received approval from OTC Mar…

*Swiss Water Decaff Coffee: TSX Approves Share Buyback Under NCIB | (MORE TO FOLLOW) Dow Jones Newswires 08-17-26 1709ET Copyright (c) 2026 Dow Jones & Company, Inc.

XP's Board Of Directors Approves The Cancellation Of Existing Treasury Class A Shares Held By The Company; Total Share Count Went From 520,292,030 To 508,500,275 After Cancellation | 4:08 PM EDT, August 17, 2026 (Benzinga Newswire) XP Inc. (NASDAQ:XP), announced today that its board of directors ha…

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™ | WASHINGTON--(BUSINESS WIRE)-- Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of…

'Trump approval falls to 33%, lowest of his presidency, Reuters/Ipsos poll finds' - Reuters | 3:05 PM EDT, August 17, 2026 (Benzinga Newswire) https://www.reuters.com/world/us/trump-approval-falls-33-lowest-his-presidency-reutersipsos-poll-finds-2026-08-17/ Write to Benzinga at editorial@benzinga.c…

Update: Almonty Industries Shares Rise After Board Approves $300 Million Buyback Plan | 02:21 PM EDT, 08/17/2026 (MT Newswires) -- (Updates with the latest stock movement in the first paragraph and headline.) Almonty Industries (ALM) shares were up over 7% in Monday trading after the company said i…

Lupin Announces Approval from U.S. FDA for Pitolisant Tablets | MUMBAI, India and NAPLES, Fla., Aug. 17, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval…

Shares of crypto-linked companies are trading higher amid a rise in Bitcoin. Catalysts may include the Trump family's crypto business, World Liberty Financial, receiving conditional approval to establish a bank, and expectations that President Trump will attend a meeting with crypto and prediction…

Acurx Pharmaceuticals shares are trading higher after the company announced that the FDA has conditionally accepted the proposed proprietary, or brand name, CIFBEZY for ibezapolstat. |

Faeth Therapeutics Shares Rise on FDA Fast-Track Designation for Cancer Treatment | Faeth Therapeutics shares rose Monday morning after the clinical-stage oncology company said the Food and Drug Administration granted fast-track designation to its experimental cancer treatment. Shares were recently…

MYND.AI, INC. RECEIVES NYSE AMERICAN APPROVAL OF COMPLIANCE PLAN AND EXTENSION THROUGH DECEMBER 2027 | NYSE American Acceptance Provides Continued Listing While Company Executes Strategic Growth and Balance Sheet Initiatives ALPHARETTA, Ga., Aug. 17, 2026 /PRNewswire/ -- Mynd.ai, Inc. ("Mynd" or th…

U.S. Food and Drug Administration Approves an Autoinjector Version of LEROCHOL® (lerodalcibep-liga) and Updated Indication | LEROCHOL is the first and only PCSK9 inhibitor with once-monthly, single-injection dose self-administered by patients with room temperature storage up to three months now app…

UroGen Pharma Submits US FDA New Drug Application for UGN-103 in Recurrent Bladder Cancer | 08:42 AM EDT, 08/17/2026 (MT Newswires) -- UroGen Pharma (URGN) submitted a new drug application to the US Food and Drug Administration for UGN-103 to treat adults with recurrent low-grade intermediate-risk…

WhiteWater-led venture approves Permian-to-Texas gas pipeline project |

TOMI Environmental Solutions Announces Ireland Approval Of BIT Solution Under EU Biocidal Products Regulation, Extending Authorizations To 11 European Markets |

TOMI Secures Critical Ireland Market Approval, Strengthening SteraMist's Position Across the European Union | FREDERICK, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today…

VivoPower Board Approves Creation Of Separate, Independent Singapore-Based AI Infrastructure Firm | 8:17 AM EDT, August 17, 2026 (Benzinga Newswire) VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructu…

VivoPower Approves Independent Listing of 2.2GW Non-Nordic AI Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control | VivoPower team has assembled a non-Nordic portfolio and pipeline in excess of 2.2GW across the GCC and ASEAN regions through sover…

FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat | 8:09 AM EDT, August 17, 2026 (Benzinga Newswire) The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These in…

Almonty Industries Approves $300 Million Buyback Program | 08:07 AM EDT, 08/17/2026 (MT Newswires) -- Almonty Industries (ALM) said Monday that its board of directors has approved a new share repurchase program of up to $300 million. The company said the program allows the purchase of up to 14.4 mi…

UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution | 8:05 AM EDT, August 17, 2026 (Benzinga Newswire) UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty…

Faeth Therapeutics Gets US FDA Fast Track Designation for Endometrial Cancer Drug Combination | 08:01 AM EDT, 08/17/2026 (MT Newswires) -- Faeth Therapeutics (FTH) has received fast track designation from the US Food and Drug Administration for the combination of sapanisertib and serabelisib with p…

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat | The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These in…

AI Financial Corporation Congratulates World Liberty Financial on OCC Preliminary Conditional Approval for National Trust Bank | LAS VEGAS, NV / ACCESS Newswire / August 17, 2026 / AI Financial Corporation (NASDAQ:AIFC)(FRA:5AR1) ("AiFi" or the "Company"), today congratulated World Liberty Financia…

Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas | 07:38 AM EDT, 08/17/2026 (MT Newswires) -- Castle Biosciences (CSTL) has received approval for the dual listing of its common stock on Nasdaq Texas, in addition to its primary listing on the Nasdaq Global Market, the company said M…

Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy | 7:36 AM EDT, August 17, 2026 (Benzinga Newswire) RAD101 is the Company…

Almonty Industries Board Approves $300M Share Repurchase Program | 7:35 AM EDT, August 17, 2026 (Benzinga Newswire) Repurchase Program Aims to Create Shareholder Value by Capturing Disconnect Between Share Price and Value of Almonty’s Strategic Tungsten Assets and Growth Prospects Ahead of Initial…

Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer | 7:33 AM EDT, August 17, 2026 (Benzinga Newswire) — Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in…

Advasa Holdings, Inc. Announces Effectiveness of Registration Statement and Approval to List Common Stock on the Nasdaq Global Market | Common Stock Expected to Begin Trading on or about August 18, 2026 Under the Ticker Symbol "ADBT" TOKYO and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Advasa Holdings…

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases | RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with t…

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer | — Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or rec…

Advasa Holdings, Inc. Announces Effectiveness of Registration Statement and Approval to List Common Stock on the Nasdaq Global Market | TOKYO and NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Advasa Holdings, Inc. (“ADVASA” or the “Company”), a fintech payment holding company providing Earned Wage Ac…

Advasa Holdings, Inc. Announces Effectiveness of Registration Statement and Approval to List Common Stock on the Nasdaq Global Market | Common Stock Expected to Begin Trading on or about August 18, 2026 Under the Ticker Symbol “ADBT” TOKYO & NEW YORK--(BUSINESS WIRE)-- Advasa Holdings, Inc. (“ADVAS…

Pulsenmore Receives Second AI Grant Within One Month As Israel Innovation Authority Approves $1.27M For SmartScan AI |

Castle Biosciences Approved For Dual Listing On Nasdaq Texas While Maintaining Primary Listing On Nasdaq Global Market |

Press Release: Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program | The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combi…

Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program | The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combined scope of ap…

Castle Biosciences Approved for Dual Listing on Nasdaq Texas | FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock d…

Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026 | MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that…

Argenx's Efgartigimod Becomes First Phase 3 Therapy To Show Statistically Significant, Clinically Meaningful Improvement In IMNM, A Subtype With No Approved Treatment | 1:22 AM EDT, August 17, 2026 (Benzinga Newswire) Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in th…